Apogee Therapeutics

Despite chronic obstructive pulmonary disease (#COPD) being the third leading cause of death worldwide, it is often not diagnosed until the disease has already progressed. On #WorldCOPDDay, we renew our commitment to bettering the lives of those with COPD through improved treatment options and advocating for appropriate earlier diagnoses. #ThinkCOPD

2026 is shaping up to be a transformative year for Apogee, with four key clinical trial readouts ahead in AD and asthma. We are well positioned to advance both our monotherapy and combination programs as we aim to transform the standard of care in I&I diseases. Listen as CEO Michael Henderson shares more with BiotechTV's Brad Loncar at #Stifel25 below.

We're pleased to share highlights of our Q3 2025 pipeline progress and financial results. We announced positive interim Phase 1 results from our first-in-human study of APG333 today, continued to advance our potential best-in-class programs toward four 2026 clinical data readouts, and recently completed a $345M public offering, extending our cash runway into the second half of 2028. More details on our website. https://lnkd.in/eQHHXqfJ

Today, we're excited to announce positive interim Phase 1 results from the first-in-human study of APG333, which demonstrated data supporting potential 3- to 6-month dosing based on a half-life of approximately 55 days across all doses tested. The results support development of a quarterly or less frequently dosed co-formulation of APG273 (APG777+APG333) for respiratory indications, potentially expanding alternatives for patients with limited treatment options. CEO Michael Henderson shares more below. https://lnkd.in/ew5PKXwY

We’re honored to be named one of BioSpace’s 2026 #BestPlacesToWork! We are a fast-paced company committed to building an exceptional culture, founded on our C.O.R.E. values: Caring, Original, Resilience and Egoless. Every A-team member helps create a culture that refuses to settle for good enough, always pushing forward in the name of the patients we seek to serve. If you’re interested in joining the team, check out our open positions here: https://lnkd.in/eSiQP3Kp

#Atopicdermatitis is more than just dry skin. This November, we're proud to support the Eczema Society of Canada, which continues to advocate for better therapies for patients worldwide. The impacts of eczema are more than what meets the eye. #ShiningALightOnEczema

Apogee management looks forward to attending several healthcare conferences in the coming weeks. More details here. https://lnkd.in/eQMpxeq6

We're pleased to announce the closing of our $345 million follow-on equity financing. These funds will support advancement of our clinical pipeline, including multiple potentially best-in-class I&I therapies. Details here. https://lnkd.in/eXey4CCn

Apogee CEO Michael Henderson has spearheaded the creation of 20+ companies, launched 40 drug development programs and led two teams to FDA approvals throughout his career. Now, he's leading the charge at Apogee as we advance multiple potential first-in-class programs through the clinic in hopes of changing the lives of those with chronic I&I conditions. This career trajectory has earned Michael a spot on this year's BioSpace #40Under40 list! We're thrilled to congratulate Michael on this achievement as he leads us in our commitment to never stopping at good enough. Read more from BioSpace. https://lnkd.in/ekqcZMzQ

#Eczema can look and feel different for each individual, but its damage is the same. For those who don't have it, #EczemaAwarenessMonth is a reminder of the detrimental effects it can have. For those who do live with it, the painful, irritated skin, sleepless nights, days missed at work and time lost with loved ones are reminder enough. At Apogee, we are dedicated to delivering long-lasting relief and improved treatment options to patients with atopic dermatitis today and everyday. Get involved this month and visit National Eczema Association for more. https://lnkd.in/egpNKwT